Antituberculosis Chemotherapy Book

Antituberculosis Chemotherapy is a comprehensive resource dedicated to the principles and practice of drug therapy for tuberculosis (TB), a major global health concern caused by Mycobacterium tuberculosis. The book provides a detailed exploration of the pharmacological, clinical, and public health aspects of TB treatment.

It covers the mechanisms of action, pharmacokinetics, and adverse effects of first-line and second-line antitubercular drugs, including isoniazid, rifampicin, ethambutol, and pyrazinamide, as well as newer agents used in drug-resistant cases. The text emphasizes standardized treatment regimens, directly observed therapy (DOT), and strategies to ensure adherence and treatment success.

Special focus is given to the management of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis, highlighting diagnostic challenges, individualized treatment plans, and emerging therapeutic options. The book also addresses co-infections such as TB-HIV, pediatric and extrapulmonary tuberculosis, and treatment considerations in special populations.

In addition, it explores global TB control programs, surveillance systems, and the role of public health policies in combating the spread of the disease. Recent advances in drug development, shorter treatment regimens, and novel therapeutic approaches are also discussed.

Designed for clinicians, researchers, public health professionals, and students, this book serves as an essential guide to understanding and effectively managing tuberculosis through modern chemotherapy practices.